* Solid Biosciences Inc SLDB.OQ SLDB.O is expected
to show a
rise in quarterly revenue when it reports results on August 12
(estimated) for the period ending June 30 2024
* The Charlestown Massachusetts-based company is expected
to
report revenue of $404.71 thousand, according to the mean
estimate from 7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Solid Biosciences Inc is
for a
loss of 65 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Solid
Biosciences
Inc is $17.50, above its last closing price of $7.45.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.65 -0.64 -0.64 Met -0.1
Dec. 31 2024 -1.04 -0.99 -1.00 Missed -1.2
Sep. 30 2023 -1.19 -1.19 -1.05 Beat 11.6
Jan. 1 0001 -1.55 -1.53 -1.25 Beat 18.6
Jan. -2.21 -2.05 -1.50 Beat 26.9
1 0001
Jan. 1 0001 -1.65 -2.82 Missed -70.7
Sep. 30 2022 -2.57 -2.67 -2.71 Missed -1.5
Jun. 30 2022 -3.07 -3.15 -3.30 Missed -4.8
This summary was machine generated August 9 at 16:32 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)